88 reports

Arthritis Care and Research; ##(##): ##-## SingHealth (2014).

  • Drug Development
  • Oral Administration
  • AbbVie Inc.
  • Galapagos NV
  • Pfizer Inc.

Arthritis Care and Research; ##(##): ##-## SingHealth (2014).

  • Drug Development
  • Oral Administration
  • Market Size
  • Astellas Pharma Inc.
  • Galapagos NV

SMALL INTESTINE CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* SMALL INTESTINE CANCER THERAPEUTICS, G## COUNTRIES, CLINICAL TRIALS BY PHASE, 2018* Country Name Phase IV Phase III Phase II/ III Phase II Phase I/ II Phase I Phase ## Total United States ## ##

  • Drug Development
  • Targeted Therapy
  • World
  • Product Initiative
  • Merck & Co., Inc.

The effectiveness of the drug is such that it covered ##% of the global anti-rheumatic products market, posing a challenge to the new pipeline products in this indication.

  • Drug Development
  • Pharmaceutical
  • Therapy
  • Company
  • Market Size
  • IMMUNOLOGY THERAPEUTICS MARKET, GLOBAL, CLINICAL TRIAL DURATION BY STAGE OF DEVELOPMENT

How antirheumatic drugs protect joints from damage in rheumatoid arthritis.

  • Drug Development
  • Oral Administration
  • AbbVie Inc.
  • Janssen Biotech, Inc.
  • Johnson & Johnson

In this trial, over ## patients will be randomized to receive one of four treatments ## mg ITI-##, ## mg ITI-##, ## mg risperidone (active control) or placebo in a ##:##:##:## ratio.

  • Drug Development
  • Neurological Disorder
  • Neurology
  • Oral Administration
  • BrainStorm Cell Therapeutics Inc.
  • Clinical Trial profile. 18 Trial Title
  • Clinical Trial profile. 25 Trial Title

The PALACE trials evaluated the efficacy and safety of OTEZLA® twice daily (BID) versus placebo in adult subjects with active psoriatic arthritis despite prior conventional disease-modifying anti-rheumatic drugs and/ or biologics.

  • Drug Development
  • Oral Administration
  • Targeted Therapy
  • World
  • Product Initiative

The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostatic hyperplasia drugs, among others.

  • Drug Development
  • United Kingdom
  • United States
  • World
  • Almac Discovery Ltd.

One unit consists of one disposable insulin pump.

  • Clinical Trial
  • Diabetes Care
  • Drug Development
  • Insulin Delivery
  • Roche Group

The prominent features of this report are - ##.

  • Drug Development
  • Targeted Therapy
  • World
  • Product Initiative
  • Novartis AG

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Drug Development
  • Oral Administration
  • Therapy
  • Pfizer Inc.

It offers products such as antirheumatic agent, antibacterial agent, antiviral agent and antifungal agent.

  • Anti-Infective
  • Dermatological Condition
  • Drug Development
  • Therapy
  • Foamix Ltd.

It runs from Mar. ## to Apr. ##.

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • Supply
  • Daewoong Pharma

The prominent features of this report are - ##.

  • Drug Development
  • Oral Administration
  • World
  • Product Initiative
  • Otsuka Pharmaceutical Co., Ltd.
  • HYALONE - PRODUCT STATUS
  • HYALONE - PRODUCT DESCRIPTION

The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostatic hyperplasia drugs, among others.

  • Drug Development
  • Oral Administration
  • United States
  • Company
  • Anika Therapeutics, Inc.

One unit refers to one disposable insulin pen.

  • Clinical Trial
  • Drug Development
  • Healthcare
  • Oral Administration
  • Pfizer Inc.
  • SHIN POONG PHARMCO LTD PIPELINE PRODUCTS & ONGOING CLINICAL TRIALS OVERVIEW
  • Dermal Filler Companies and Product Overview

The company provides drugs such as psychoneurotic, anti-cancer, cardiovascular, antihistamine, antirheumatic and benign prostatic hyperplasia drugs, among others.

  • Clinical Trial
  • Drug Development
  • Therapy
  • United States
  • Sinclair Pharma plc

The prominent features of this report are - ##.

  • Autoimmune Disease
  • Clinical Trial
  • Drug Development
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Drug Development
  • Medical Biotechnology
  • Pharmaceutical
  • World
  • Product Initiative

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Drug Development
  • Medical Biotechnology
  • Monoclonal Antibody
  • Oral Administration
  • World

The molecules developed by Companies in Pre-Registration, Filing rejected/ Withdrawn, Phase III, Phase II, Phase I, IND/ CTA Filed, Preclinical, Discovery and Unknown stages are ##, ##, ##, ##, ##, ##, ##, ## and ## respectively.

  • Drug Development
  • Hospital
  • United States
  • Product Initiative
  • Nymox Pharmaceutical Corporation

The Board of Directors of GSK Pharma had announced a bonus issue of shares in the ratio of one share for every one share held (##:##) on ## July this year.

  • Drug Development
  • Oral Administration
  • Pharmaceutical
  • United States
  • Company
  • 5. All the trials included are unique trials.

(Stage ##) and s. c.

  • Drug Development
  • Oral Administration
  • Pharmaceutical
  • Therapy
  • World

The prominent features of this report are - ##.

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • World
  • Product Initiative
  • Clinical Trial profile. 243 Trial Title
  • 3. GDCT ID is the unique ID of GlobalData's Pharma Intelligence Center clinical trial database

The prominent features of this report are - ##.

  • Chronic Pain
  • Drug Development
  • Oral Administration
  • World
  • Pain Therapeutics

One external remote patient monitoring device consists of one external module or transmitter.

  • Clinical Trial
  • Drug Development
  • Pharmaceutical
  • United States
  • Pfizer Inc.

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Drug Development
  • Medical Biotechnology
  • Oral Administration
  • Therapy
  • World

The Impact of Antirheumatic Treatment on Antibody Response and Protection of Infections (Vaccimil) Vaccination in Inflammatory Rheumatic Disease (VACCIMIL).

  • Cardiology
  • Drug Development
  • Medical Biotechnology
  • Oral Administration
  • World

SUBJECTS ARE MAINTAINED ON EACH DOSE FOR AT LEAST TWO TO THREE CONSECUTIVE WEEKS (ONE WEEK STABILIZATION + ONE AND A HALF WEEKS TESTING).

  • Drug Development
  • Hospital
  • Oral Administration
  • Therapy
  • MediciNova, Inc.
  • 5. All the trials included are unique trials.

(Stage ##) and s. c.

  • Drug Development
  • Medical Biotechnology
  • Oral Administration
  • Pharmaceutical
  • World